On 22 October, the company experienced an information security incident and consequently isolated the impacted IT services. This incident involved a ransom-ware attack.
Hyderabad firm becomes the first Indian and the third Asian pharmaceutical company to have set its Science-Based Targets to further minimise environmental impact
“We are pleased with the settlement agreement, and look forward to bringing a generic version of lenalidomide to market soon subject to regulatory approval for the benefit of patients.”
Remdesivir is approved by Drug Controller General of India (DCGI) for restricted emergency use in India for the treatment of Covid-19 patients hospitalised with severe symptoms. Redyx is available in a strength of 100 mg vial.
Commenting on his appointment, Dr. Reddy said, “SRU ranks among the top 160 institutions in India and 5th in Telangana as per NIRF-MHRD.
As per the non-exclusive licensing agreement, Gilead will grant the Hyderabad-based drug maker the right to register and manufacture its investigational drug Remdesivir in 127 countries, Dr Reddy's Laboratories said in a statement.
Warangal Urban: Dr R Mallikarjuna Reddy took charge as Head of the Department of Geology, Kakatiya University (KU) on Monday. His appointment order was...
Mumbai: Equity benchmark indices slipped by 2.7 per cent during early hours on Tuesday in line with Asian peers after US oil prices slipped...
G V Prasad, the co-chairman and managing director of Dr Reddy’s said, “India is an important market for us and this acquisition will help in considerably scaling-up our domestic business."
Commenting on the financial results, Dr Reddy’s co-chairman and managing director, GV Prasad said "I am pleased with our performance across the businesses and strong cash generation during the quarter. We are progressing well in execution of our strategy and in our transformation journey on quality and efficiency."
The product is a generic version of Lundbeck's Sabril powder for oral solution, Dr Reddy's said in a filing to the BSE
The USFDA had issued warning letter in November 2015 relating to Current Good Manufacturing Practice (CGMP) deviations at DR Reddy's API manufacturing facilities at Srikakulam in AP and Miryalaguda in Telangana besides its oncology formulation facility at Duvvada, Visakhapatnam
Among stocks, UPL gained 2.7 per cent while Yes Bank continued its upward slide by 2.3 per cent. Zee Entertainment, Kotak Mahindra Bank and Tech Mahindra also traded in the green.
The gains were more pronounced in metal and pharma stocks. All sectoral indices except for Nifty IT were in the green at the National Stock Exchange.
The Indian drug maker in a regulatory filing said its top ten customers in the USA account for approximately 77 per cent of the revenues from North America Global Generics
The court in New Jersey imposed the fine after a complaint that Dr Reddy Laboratories (DRL) failed to comply with the Poison Prevention Packaging Act (PPPA) and the Consumer Product Safety Act (CPSA).